As the UK sterling nears parity with the euro and the competitive prospects for EU economies are not particularly optimistic, there are some positives to take into the new year.
UK biotech leaders have made an unprecedented plea for state funding, claiming that a major cash injection is the only hope for the industry's survival.
Global prescription sales growth of generics slowed to 3.6% in the twelve months ending September 2008, down from 11.4% in 2007, according to a new report by IMS Health.
